The wealthy and highly lucrative medtech firm Coloplast needs to let go of some of its caution, release the billions and acquire either new firms or technology, according to several industry actors.
"If your strategy involves acquisitions, you have to acquire. Just like if your strategy is to be a digital frontrunner or to be best at marketing. You have to invest in your strategy," says ABG Sundal Collier Jannick Lindegaard Denholt. He is far from alone in his views:
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.